8-K: Dianthus Therapeutics Reports Q4 and Full Year 2024 Financial Results and Highlights Clinical Program Progress

Dianthus Therapeutics announced its Q4 and full year 2024 financial results, highlighting the progress of its clinical trials for DNTH103 and a cash runway into 2H27.

Summary

• Dianthus Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company's Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) is ongoing, with top-line results expected in 2H25.
• The Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is ongoing, with an interim responder analysis anticipated in 2H26.
• The Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) is ongoing, with top-line results anticipated in 2H26.
• Dianthus Therapeutics had $357.0 million in cash as of December 31, 2024, which is projected to provide runway into the second half of 2027.
• Research and development (R&D) expenses for the year ended December 31, 2024, were $83.1 million, including $5.6 million of stock-based compensation.
• General and administrative (G&A) expenses for the year ended December 31, 2024, totaled $25.0 million, including stock-based compensation of $7.3 million.
• The net loss for the year ended December 31, 2024, was $85.0 million, or $2.55 per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, a strong cash position, and the strengthening of the leadership team. However, the increased net loss and expenses temper the overall sentiment.

Positives

• The company has a strong cash position of $357.0 million, providing a runway into the second half of 2027.
• Clinical trials for DNTH103 are progressing as planned, with key data readouts expected in the near future.
• The company has strengthened its leadership team with the appointment of a new Chief Commercial Officer and a new board member.

Negatives

• The company reported a net loss of $85.0 million for the year ended December 31, 2024, which is higher than the previous year's net loss of $43.6 million.
• R&D expenses increased significantly to $83.1 million, driven by higher clinical costs and increased headcount.
• G&A expenses also increased to $25.0 million due to increased headcount and higher professional services costs.

Risks

• Clinical trial results may not be predictive of the results or success of ongoing or later clinical trials.
• The development of DNTH103 may take longer and/or cost more than planned.
• The company may be unable to successfully complete the clinical development of its compounds.
• The company may be delayed in initiating, enrolling, or completing its planned clinical trials.
• The company's compounds may not receive regulatory approval or become commercially successful products.

Future Outlook

The company anticipates reporting top-line data from the Phase 2 MaGic trial in gMG in 2H25, an interim responder analysis of the Phase 3 CAPTIVATE trial in CIDP in 2H26, and top-line data from the Phase 2 MoMeNtum trial in MMN in 2H26; the current cash position is expected to fund operations into 2H27.

Management Comments

• We remain on track to report top-line data in 2H25 from our Phase 2 clinical trial of DNTH103 in gMG, an indication where a best-in-class, potent active C1s and classical pathway inhibitor with the potential for effective and consistent symptom control along with improved safety and convenience could meaningfully advance the standard of care, said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics.
• We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP, which is on track for an interim responder analysis in 2H26, along with top-line results from our Phase 2 trial in MMN.

Industry Context

Dianthus Therapeutics is focused on developing antibody complement therapeutics for severe autoimmune diseases, a competitive area with significant unmet need. The company's focus on selective inhibition of the classical complement pathway with DNTH103 aims to offer improved safety and convenience compared to existing treatments.

Comparison to Industry Standards

• Dianthus is developing DNTH103, a monoclonal antibody targeting the classical complement pathway, similar to how companies like Alexion Pharmaceuticals (now part of AstraZeneca) developed Soliris and Ultomiris, which target the terminal complement pathway (C5).
• Unlike broad complement inhibitors, DNTH103 selectively inhibits the active form of C1s protein, potentially reducing the risk of infection from encapsulated bacteria, a common concern with drugs like Soliris and Ultomiris.
• The company's focus on subcutaneous administration of DNTH103 every two weeks aims to improve patient convenience compared to intravenous infusions required for some existing complement inhibitors.

Management Changes

Stakeholder Impact

• Shareholders: The progress of clinical trials and strong cash position are positive for shareholders.
• Employees: Increased headcount suggests potential job growth and stability.
• Patients: Successful development of DNTH103 could provide a new treatment option for severe autoimmune diseases.

Next Steps

• Report top-line data from the Phase 2 MaGic trial in gMG in 2H25.
• Conduct an interim responder analysis of the Phase 3 CAPTIVATE trial in CIDP in 2H26.
• Report top-line data from the Phase 2 MoMeNtum trial in MMN in 2H26.
• File Form 10-K with the SEC for additional financial information.

Key Dates